Next generation weight loss drugs are prohibitively expensive for many in the US who would benefit from taking them—and may remain so, thanks to the phenomenon of patent thickets. Paige Huffman ...

Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock ...

As the body positivity era gives way to a “thin is in” moment, telehealth platforms are seizing the opportunity to cash in. Increasingly, their marketing is positioning blockbuster weight-loss shots ...

Eli Lilly briefly became the first healthcare company to reach a $1 trillion market value, fueled by its blockbuster ...

Key Takeaways GLP-1 weight-loss drugs such as tirzepatide are known to curb appetite, but effects on out-of-control eating ...

ELI Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a far different reason: the weight-loss bonanza.

President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly ...